Welcome to our dedicated page for Fibrobiologics SEC filings (Ticker: FBLG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to decode FibroBiologics’ dense clinical disclosures? A single FBLG 10-K weaves together patent counts, Phase I/II trial outcomes, and cash-runway tables—information critical yet hard to locate. Whether you’re hunting for FibroBiologics insider trading Form 4 transactions before the next catalyst or need the fine print on manufacturing agreements buried in an 8-K, the complexity is real.
Stock Titan solves that problem. Our AI reads every new submission to EDGAR the moment it posts, then delivers plain-English explanations, key metric highlights, and red-flag alerts. Open any FibroBiologics quarterly earnings report 10-Q filing and you’ll see R&D spend trends, trial burn-rates, and liquidity ratios laid out clearly. Curious about governance? Review the latest FibroBiologics proxy statement executive compensation with side-by-side pay-versus-performance visuals—no accounting degree required.
Here’s what you can explore today:
- FibroBiologics annual report 10-K simplified—understand risk factors around clinical success rates and IP challenges.
- FibroBiologics Form 4 insider transactions real-time—track executive stock moves minutes after filing.
- FibroBiologics 8-K material events explained—see how new trial data or FDA meetings may shift timelines.
Every document comes with fast search, downloadable tables, and AI-powered summaries, so understanding FibroBiologics SEC documents with AI becomes part of your daily workflow—not a weekend project. Use our FibroBiologics earnings report filing analysis to compare quarter-over-quarter progress, catch dilution risks early, and monitor FibroBiologics executive stock transactions Form 4 without sifting through PDFs. Complex biotech filings made clear, updated in real time.
comScore, Inc. (SCOR) – Form 4 insider filing
Director Matthew F. McLaughlin received an equity grant of 10,000 restricted stock units (RSUs) on 07/01/2025 under the company’s 2018 Equity and Incentive Compensation Plan. Each RSU represents one share of common stock.
Vesting schedule: the award vests in full on the earliest of (i) the 2026 annual shareholder meeting, (ii) 30 June 2026, or (iii) a change-of-control event, subject to continued board service. Shares are delivered after separation from service or a change of control.
Compensation changes: the grant’s fair-value target is $120,000, calculated by dividing the target amount by a reference price of $12.00. This represents a significant reduction from the prior director compensation formula, which allocated $170,000 divided by the market price at grant (previously $5.07). The Board reduced overall compensation and applied a higher share price to more closely align directors’ incentives with long-term shareholder value.
Post-transaction ownership: McLaughlin now beneficially owns 10,000 derivative securities (RSUs) held directly; no non-derivative common shares were reported.
The filing is routine and involves no open-market transactions, cash outflow, or immediate dilution; it primarily signals a shift in board compensation structure rather than a material operational event.
FAQ
What is the current stock price of Fibrobiologics (FBLG)?
What is the market cap of Fibrobiologics (FBLG)?
What is the core focus of FibroBiologics?
How does FibroBiologics utilize fibroblast cells in its therapies?
Which therapeutic areas does FibroBiologics target?
What distinguishes FibroBiologics from other biotech companies?
Which partnerships support FibroBiologics' clinical development?
How does the company contribute to advancements in regenerative medicine?
What role does the patent portfolio play for FibroBiologics?
Is FibroBiologics already in the clinical trial phase?
